A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

← catalyst calendar

NCT07226843 · readout ≤ 254 d

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

460estimated

Sites

Countries

France, Germany, Italy +5

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-04-17

actual

When the study began enrolling

Primary completion

Apr 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Feb 2030

estimated

The whole study's end, after follow-up

First posted

2025-11-12

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-06

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Lymphoma, Non-Hodgkin's
Lymphoma, Diffuse Large B-Cell
Follicular Lymphoma

Interventions

Drug: LY4584180
Drug: Rituximab

Primary outcomes

what the primary-completion date above is the date OF

Number of Dose-Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities

measured Baseline up to Day 28

Number of Participants with One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration

measured Baseline up to 3 Years

To Evaluate the Preliminary Antitumor Activity of LY4584180: Objective Response Rate (ORR)

measured Baseline up to 3 Years

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed